Drug intelligence / Profile preview

YZ-0382

Development stage: Preclinical
Lead developer: Guangdong Yinzhu Pharmaceutical Technology
Modality: Small Molecules

Overview

YZ-0382 is a preclinical-stage small molecule inhibitor targeting the **NF-κB** (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway. Developed by **Guangdong Yinzhu Pharmaceutical Technology**, the compound is being investigated for the treatment of various solid tumors, including pancreatic, ovarian, fallopian tube, peritoneal, and prostate cancers. Additionally, it is being explored as part of a fixed-dose combination for the treatment of breast cancer. NF-κB is a critical transcription factor that regulates genes involved in inflammation, cell survival, and immune responses; its dysregulation is frequently associated with tumor progression, apoptosis evasion, and resistance to chemotherapy.

Other names: YZ-0382YZ0382YZ 0382

Targets

NF-κB

Beyond the preview

Go deeper on YZ-0382.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YZ-0382.

Explore the full profile